Ifosfamide: An active drug in the treatment of adenocarcinoma of the pancreas

P. J. Loehrer, S. D. Williams, L. H. Einhorn, R. Ansari

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

From April 1982, until February 1984, 29 patients with biopsy-proven and measurable adenocarcinoma of the pancreas were treated with ifosfamide. Ifosfamide was administered at a dose of 1.25 to 1.5 g/m2 daily for five consecutive days with courses repeated every three weeks. If no serious toxicity was noted, subsequent dosages were escalated to a maximum of 2.0 g/m2/d. In addition, N-acetylcysteine (NAC) (8 to 12 g/d) was administered (in divided daily doses days 1 through 7) as a urothelial protective agent. Nausea and vomiting occurred in the majority of the treated patients. Other toxicities noted were mild myelosuppression, CNS toxicity, and one case of acute renal failure. One complete response (CR) and five partial responses (PR) were observed in 27 evaluable patients (CRs and PRs = 22%). Ifosfamide has definite activity against pancreatic adenocarcinoma. Doses > 1.2 g/m2 for days 1 through 5 can be administered without significant toxicity in the majority of patients. Further trials with ifosfamide alone and/or with other agents are warranted.

Original languageEnglish (US)
Pages (from-to)367-372
Number of pages6
JournalJournal of Clinical Oncology
Volume3
Issue number3
DOIs
StatePublished - Jan 1 1985

Fingerprint

Ifosfamide
Pancreas
Adenocarcinoma
Pharmaceutical Preparations
Protective Agents
Acetylcysteine
Therapeutics
Acute Kidney Injury
Nausea
Vomiting
Biopsy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ifosfamide : An active drug in the treatment of adenocarcinoma of the pancreas. / Loehrer, P. J.; Williams, S. D.; Einhorn, L. H.; Ansari, R.

In: Journal of Clinical Oncology, Vol. 3, No. 3, 01.01.1985, p. 367-372.

Research output: Contribution to journalArticle

@article{e8292b6c22f0424892e18a0fde8f59fc,
title = "Ifosfamide: An active drug in the treatment of adenocarcinoma of the pancreas",
abstract = "From April 1982, until February 1984, 29 patients with biopsy-proven and measurable adenocarcinoma of the pancreas were treated with ifosfamide. Ifosfamide was administered at a dose of 1.25 to 1.5 g/m2 daily for five consecutive days with courses repeated every three weeks. If no serious toxicity was noted, subsequent dosages were escalated to a maximum of 2.0 g/m2/d. In addition, N-acetylcysteine (NAC) (8 to 12 g/d) was administered (in divided daily doses days 1 through 7) as a urothelial protective agent. Nausea and vomiting occurred in the majority of the treated patients. Other toxicities noted were mild myelosuppression, CNS toxicity, and one case of acute renal failure. One complete response (CR) and five partial responses (PR) were observed in 27 evaluable patients (CRs and PRs = 22{\%}). Ifosfamide has definite activity against pancreatic adenocarcinoma. Doses > 1.2 g/m2 for days 1 through 5 can be administered without significant toxicity in the majority of patients. Further trials with ifosfamide alone and/or with other agents are warranted.",
author = "Loehrer, {P. J.} and Williams, {S. D.} and Einhorn, {L. H.} and R. Ansari",
year = "1985",
month = "1",
day = "1",
doi = "10.1200/JCO.1985.3.3.367",
language = "English (US)",
volume = "3",
pages = "367--372",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Ifosfamide

T2 - An active drug in the treatment of adenocarcinoma of the pancreas

AU - Loehrer, P. J.

AU - Williams, S. D.

AU - Einhorn, L. H.

AU - Ansari, R.

PY - 1985/1/1

Y1 - 1985/1/1

N2 - From April 1982, until February 1984, 29 patients with biopsy-proven and measurable adenocarcinoma of the pancreas were treated with ifosfamide. Ifosfamide was administered at a dose of 1.25 to 1.5 g/m2 daily for five consecutive days with courses repeated every three weeks. If no serious toxicity was noted, subsequent dosages were escalated to a maximum of 2.0 g/m2/d. In addition, N-acetylcysteine (NAC) (8 to 12 g/d) was administered (in divided daily doses days 1 through 7) as a urothelial protective agent. Nausea and vomiting occurred in the majority of the treated patients. Other toxicities noted were mild myelosuppression, CNS toxicity, and one case of acute renal failure. One complete response (CR) and five partial responses (PR) were observed in 27 evaluable patients (CRs and PRs = 22%). Ifosfamide has definite activity against pancreatic adenocarcinoma. Doses > 1.2 g/m2 for days 1 through 5 can be administered without significant toxicity in the majority of patients. Further trials with ifosfamide alone and/or with other agents are warranted.

AB - From April 1982, until February 1984, 29 patients with biopsy-proven and measurable adenocarcinoma of the pancreas were treated with ifosfamide. Ifosfamide was administered at a dose of 1.25 to 1.5 g/m2 daily for five consecutive days with courses repeated every three weeks. If no serious toxicity was noted, subsequent dosages were escalated to a maximum of 2.0 g/m2/d. In addition, N-acetylcysteine (NAC) (8 to 12 g/d) was administered (in divided daily doses days 1 through 7) as a urothelial protective agent. Nausea and vomiting occurred in the majority of the treated patients. Other toxicities noted were mild myelosuppression, CNS toxicity, and one case of acute renal failure. One complete response (CR) and five partial responses (PR) were observed in 27 evaluable patients (CRs and PRs = 22%). Ifosfamide has definite activity against pancreatic adenocarcinoma. Doses > 1.2 g/m2 for days 1 through 5 can be administered without significant toxicity in the majority of patients. Further trials with ifosfamide alone and/or with other agents are warranted.

UR - http://www.scopus.com/inward/record.url?scp=0021920111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021920111&partnerID=8YFLogxK

U2 - 10.1200/JCO.1985.3.3.367

DO - 10.1200/JCO.1985.3.3.367

M3 - Article

C2 - 3973647

AN - SCOPUS:0021920111

VL - 3

SP - 367

EP - 372

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -